Medic Bleep is a simple, secure and innovative patient-focused solution to communication challenges that healthcare professionals and the wider team in the UK National Health Service (NHS) face while going about their everyday work. It is saving each nurse & each junior doctor an estimated 48 minutes per shift. This coincides with the UK's Department of Health calling for a ban on pagers. If implemented across the NHS, it could free up the time to care for an estimated 11,000 nurses. To ensure data privacy and safety, the company allows communication to occur via the app. As a result of these safeguards and its user-friendly portal, the company's app has been downloaded 16,000 times by UK doctors and nurses. With the funds raised, the company will aim to solve looming technology gaps for over 30% of the NHS in the next 3 years and expand globally.
days to go:
Expired
investment:
£814,600
Graphene Composites is a nano-materials technology company that creates the strongest, lightest, most resilient material by combining aerogel, graphene, and other nano-materials. Founded in 2016, the company, in partnerships with US/Global defence/aerospace contractor, is one of the few graphene nanotechnology companies who are developing bulletproof graphene/aerogel armour. Moreover, it is also extending its GC Shield technology to military/police applications. Besides these, GC's technology can also be used to improve the strength and reliability of wind turbines.
days to go:
Expired
investment:
£597,360
Grow is a British biopharmaceutical company on a mission to unlock the potential of cannabis medicines for patients globally. It claims that it is one of the largest importers of cannabis medicines in the UK and Ireland since its founding in 2017. The company has raised over £9.5 million through several fundraising rounds to allow expansion of operations, supplied medicines to more than 1,200 patients a month as of June 2021, and earned £2.35 million in revenue as of July 20, 2021. The company has also launched its patient app, Calyx, to help patients track their medications and health indicators and signed long term partnerships with some of the world’s leading cannabis companies, including Aurora, Tilray and Columbia Care. The company argues that it has also pioneered the ‘Open Cannabis’ campaign to improve education on cannabis medicines and the means to access them in the UK. It states it will use 40% of the investment on capital expenditure, 30% on hiring new personnel, and 30% as working capital.
days to go:
Expired
investment:
£3,566,133
Particity is a platform that allows researchers to hire participants for a research project, collaborate with them, and approve participant incentives all on a single portal. The company argues that its portal automates what is currently a tedious and manual process and brings operational costs of a project down to a viable level. Particity claims that its model allows entities from Small and Medium Enterprises (SME) to marketing and research agencies, witness business growth. It has received enquiries from enterprises such as Oxford University, Discovery INC and PPD. Particity endeavours to become a contender in the $345 billion logistics and efficiency market and deliver an end-to-end solution to its clients. The potential exit opportunities for Particity would be to a player in the research industry, consultancy, software and digital or private equity.
days to go:
Expired
investment:
Withheld
Clin-e-cal is a medical technology company that has created a 'Clip-Tone Buddy' app. The app uses Clin-e-cal's patented Sound Response (SR) technology to give real-time feedback helping patients understand how to use their inhalers correctly. The company intends to become a disruptor in the estimated £300 million inhaler technology market. It asserts that its app can help streamline clinical trials, identify patients most at risk and impact future respiratory device design. Clin-e-cal was short-listed for the Tech4Good award 2020 and rated 79% by The Organisation for the Review of Care and Health Applications (ORCHA). Clin-e-cal will use the investment to progress commercialisation of the Clip-Tone Buddy, scale its sales activity, and optimise the company's marketing, regulatory and legal aspects.
days to go:
Expired
investment:
£132,354
Oyako is a distance-control application that aims to reduce the stresses and strains on children's eyes. The company asserts that an increase in mobile technology usage has led to an increase in myopia (nearsightedness) in children. It also leads to parents incurring a cost by way of purchasing spectacles along with a cost to the National Health Service (NHS) and medical insurance companies. By 2050, half of the global population will be short-sighted if current trends continue. Oyako aims to solve this issue through its application. Oyako's prototype app uses a simple traffic light design to signify safe or damaging scenarios, intelligently controls the phone camera without compromising battery usage, and is available on the App Store and Google Playstore. Oyako will use the investment to finalise its application and take it to market at £6.99 per download.
days to go:
Expired
investment:
£131,641
Coconut automates bookkeeping and tax for sole traders. The company argues that in the next 24 months, 3.5 million sole traders in the UK will be required to complete 4 tax submissions a year instead of 1, in light of Her Majesty's Revenue and Customs (HMRC's) Making Tax Digital (MTD) initiative. Coconut aspires to become the leading sole trader finance and MTD product in the UK targeting the aforementioned audience. Coconut asserts that its total revenue grew by 174% in 2020 despite COVID-19. It also claims to have onboarded 8,000 paying customers, registered a 174% revenue growth in 2020, and signed 2,800 accountants on its portal to date. Coconut connects with over 25 banks, giving automatic tax insights using banking data based on the principles of 'Open Banking'. The company will use the investment to target 100 million+ self-employed businesses in Europe and North America and grow its business across different verticals.
days to go:
Expired
investment:
£2,006,334
Jobmate helps Small and Medium Enterprises (SMEs) manage tasks such as preparing invoices, scheduling meetings and complying with regulations through its application. The company asserts that its app is customisable and enables SME owners to have a work-life balance. It also aims to create a community of professionals that can cooperate, increase their work opportunities, and earn higher profits through the app. Jobmate is targeting 20,000 subscribers in year one and 650,000 by year five. The company will use the investment to take its product to launch through the latest innovative digital marketing, established networks and distribution partners.
days to go:
Expired
investment:
£410,704
LONDCAP is a mobile app that uses Artificial Intelligence (AI) and machine learning to enhance a customer's credit profile and make borrowing more accessible. The company aims to enable credit cards access to customers without credit history or national insurance number. It also endeavours to facilitate loan and mortgage approvals via its app. LONDCAP provides a live exchange money service at inter-bank rates as an approved licensee under the Financial Conduct Authority (FCA) laws. It has a network of over 30,000 companies and over 40,000 investors as of March 2020. The company will use the investment to achieve 50,000 monthly active users, prepare the business for the Series A fundraising round, build its team across different specialities, and launch a comprehensive app on the App Store and Google Playstore in partnership with financial entities like IBAN, SWIFT and SEPA.
days to go:
Expired
investment:
£108,373
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
